Aptadel Therapeutcs technology is based in RNA-Aptamers. We use our Aptamers as a platform tool to deliver different therapeutic agents with high specificity and improved safety to treat a wide variety of cancers.

Changing The Way We Treat Cancer

Aptamer technologies represent a revolutionary advancement in the capacity to rapidly develop new classes of targeting ligands. Aptamers are nucleic acids with complex tertiary folded structures that exhibit high binding affinity and selectivity for their targets, and are often refer to as “chemical antibodies”. This is because, unlike antibodies, aptamers can be readily chemically synthesized and modified. Due to their flexibility of chemical modification, aptamers can be conjugated to other chemical entities including chemotherapeutic agents, siRNA, nanoparticles, and solid phase surfaces for therapeutic and diagnostic applications.

We have generated an RNA aptamer specific for the receptor tyrosine kinase EphA2 by cellinternalization SELEX. Thus, this aptamer not only recognizes EphA2 but also internalizes upon binding, delivering intracellularly its drug cargo. EphA2 is implicated in many processes crucial to malignant progression, such as migration, invasion, metastasis, proliferation, survival, and angiogenesis; and is overexpressed in a wide variety of solid tumors. We propose a radically innovative treatment for EphA2 expressing tumors based on multifunctional RNA-based molecules capable of targeting EphA2 and key targets of specific cancer types.

Scientific Publications

Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors

EphA2 receptor is a key player in the metastatic onset of Ewing Sarcoma

Silvia Garcia-Monclús, Roser López-Alemany, Olga Almacellas-Rabaiget, David Herrero-Martín, Juan Huertas-Martinez, Laura Lagares-Tena, Piedad Alba-Pavón, Lourdes Hontecillas-Prieto, Jaume Mora, Enrique de Álava, Santi Rello-Varona, Paloma H. Giangrande, and Oscar M Tirado

Int J Cancer. 2018 Sep 1; 143(5): 1188–1201.

EphA2-induced angiogenesis in Ewing Sarcoma cells works through bFGF production and is dependent on caveolin-1

Miguel Sáinz-Jaspeado, Juan Huertas-Martinez, Laura Lagares-Tena, Juan Martin Liberal, Silvia Mateo-Lozano, Enrique de Alava, Carmen de Torres, Jaume Mora, Xavier Garcia del Muro, and Oscar M. Tirado

PLoS One. 2013; 8(8): e71449.